Levodopa and Parkinson disease--electrophysiological perspectives in animal models.
Identifieur interne : 001642 ( Main/Exploration ); précédent : 001641; suivant : 001643Levodopa and Parkinson disease--electrophysiological perspectives in animal models.
Auteurs : Fariborz Rahimi [Canada] ; Marei Typlt ; Mandar S. JogSource :
- Experimental neurology [ 1090-2430 ] ; 2011.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Levodopa.
- physiology : Action Potentials, Neurons, Substantia Nigra, Subthalamic Nucleus.
- physiopathology : Parkinsonian Disorders.
- Animals, Female.
Abstract
Chronic administration of levodopa, while producing an "awakening" in patients with Parkinson disease (PD), causes disabling side effects such as motor fluctuations and dyskinesia. Indeed the most common reason for deep brain stimulation (DBS) in patients with PD is for treating these complications. However, our understanding of the complexities of these complications is still in the early days. Animal models (primate and rodent) have been exceedingly helpful in elucidating some of the mechanisms. More work needs to be done. In the paper by Gilmour et al. (2011) the authors have investigated the neuronal firing properties and local field potentials of two basal ganglia structures, in response to chronic treatment, to tackle this very question. This commentary attempts to place the work in the context of PD animal models, electrophysiology and where we need to go.
DOI: 10.1016/j.expneurol.2011.05.012
PubMed: 21640724
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B82
- to stream PubMed, to step Curation: 000B82
- to stream PubMed, to step Checkpoint: 000B82
- to stream Ncbi, to step Merge: 000E90
- to stream Ncbi, to step Curation: 000E90
- to stream Ncbi, to step Checkpoint: 000E90
- to stream Main, to step Merge: 001710
- to stream Main, to step Curation: 001642
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa and Parkinson disease--electrophysiological perspectives in animal models.</title><author><name sortKey="Rahimi, Fariborz" sort="Rahimi, Fariborz" uniqKey="Rahimi F" first="Fariborz" last="Rahimi">Fariborz Rahimi</name><affiliation wicri:level="1"><nlm:affiliation>London Health Sciences Centre & University of Western Ontario, London Health Sciences Centre, 339 Windermere Road, Room B10-131, London ON, Canada, N6A 5A5. frahimi@uwo.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Typlt, Marei" sort="Typlt, Marei" uniqKey="Typlt M" first="Marei" last="Typlt">Marei Typlt</name></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21640724</idno><idno type="pmid">21640724</idno><idno type="doi">10.1016/j.expneurol.2011.05.012</idno><idno type="wicri:Area/PubMed/Corpus">000B82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B82</idno><idno type="wicri:Area/PubMed/Curation">000B82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B82</idno><idno type="wicri:Area/PubMed/Checkpoint">000B82</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B82</idno><idno type="wicri:Area/Ncbi/Merge">000E90</idno><idno type="wicri:Area/Ncbi/Curation">000E90</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E90</idno><idno type="wicri:Area/Main/Merge">001710</idno><idno type="wicri:Area/Main/Curation">001642</idno><idno type="wicri:Area/Main/Exploration">001642</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa and Parkinson disease--electrophysiological perspectives in animal models.</title><author><name sortKey="Rahimi, Fariborz" sort="Rahimi, Fariborz" uniqKey="Rahimi F" first="Fariborz" last="Rahimi">Fariborz Rahimi</name><affiliation wicri:level="1"><nlm:affiliation>London Health Sciences Centre & University of Western Ontario, London Health Sciences Centre, 339 Windermere Road, Room B10-131, London ON, Canada, N6A 5A5. frahimi@uwo.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Typlt, Marei" sort="Typlt, Marei" uniqKey="Typlt M" first="Marei" last="Typlt">Marei Typlt</name></author><author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name></author></analytic><series><title level="j">Experimental neurology</title><idno type="eISSN">1090-2430</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action Potentials (physiology)</term><term>Animals</term><term>Female</term><term>Levodopa (administration & dosage)</term><term>Neurons (physiology)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Substantia Nigra (physiology)</term><term>Subthalamic Nucleus (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Action Potentials</term><term>Neurons</term><term>Substantia Nigra</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Chronic administration of levodopa, while producing an "awakening" in patients with Parkinson disease (PD), causes disabling side effects such as motor fluctuations and dyskinesia. Indeed the most common reason for deep brain stimulation (DBS) in patients with PD is for treating these complications. However, our understanding of the complexities of these complications is still in the early days. Animal models (primate and rodent) have been exceedingly helpful in elucidating some of the mechanisms. More work needs to be done. In the paper by Gilmour et al. (2011) the authors have investigated the neuronal firing properties and local field potentials of two basal ganglia structures, in response to chronic treatment, to tackle this very question. This commentary attempts to place the work in the context of PD animal models, electrophysiology and where we need to go.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name><name sortKey="Typlt, Marei" sort="Typlt, Marei" uniqKey="Typlt M" first="Marei" last="Typlt">Marei Typlt</name></noCountry><country name="Canada"><noRegion><name sortKey="Rahimi, Fariborz" sort="Rahimi, Fariborz" uniqKey="Rahimi F" first="Fariborz" last="Rahimi">Fariborz Rahimi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001642 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001642 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21640724
|texte= Levodopa and Parkinson disease--electrophysiological perspectives in animal models.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21640724" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |